Sun Life (SLF) Q1 2026 earnings review
Core Business Holds, But One-Offs and Asset Management Drag
Sun Life's Q1 2026 results reveal a stark divergence between operating performance and statutory results. While Underlying Net Income remained Stable at $1.05 billion (+0.4% YoY), Reported Net Income collapsed 50% to $465 million. This massive $585 million gap was driven by a $165M charge to finalize the BGO and Crescent buyouts, a $145M legal settlement, and $247M in negative market impacts. The core insurance engines (Asia and Canada) are firing on all cylinders, but the Asset Management pillar—which Sun Life has aggressively deployed capital to build—is struggling. MFS suffered another US$16.3 billion in net outflows, and SLC Management earnings dropped 25%. Management insists 2026 is a 'transition year' for SLC, but with the LICAT capital buffer dropping 14 points to 143%, the margin for execution error has narrowed.
🐂 Bull Case
Asia delivered record performance with individual insurance sales Accelerating by 41% YoY (exceeding $1B in a quarter for the first time). Hong Kong alone surged 75%, driving total Asia underlying net income up 17%.
After a volatile 2025, the U.S. medical stop-loss business is Reversing course. Disciplined repricing (+17% rate increases) combined with a hardening market drove a 43% spike in Q1 sales and an $8M improvement in morbidity experience.
🐻 Bear Case
MFS continues to hemorrhage assets with US$16.3B in Q1 retail outflows. Meanwhile, SLC Management's underlying net income fell 25% YoY (US$32M vs US$59M) due to a lack of catch-up fees and lower seed capital income.
The SLF LICAT ratio plunged from a massive 157% in Q4 to 143% in Q1. While 10 points of this drop was intentionally used to fund the $2.4B BGO/Crescent buyouts, it materially reduces excess capital available for aggressive buybacks.
⚖️ Verdict: ⚪
Neutral. The protection businesses (Asia, Canada, U.S. Stop-Loss) are highly robust and growing. However, Sun Life's heavy strategic pivot toward Asset Management is currently a drag on earnings, requiring investors to wait for a promised H2 2026 rebound.
Key Themes
Asia's Relentless Momentum
Asia remains Sun Life's premier growth engine. The region's underlying net income is Accelerating, up 17% YoY to $216M. Individual insurance sales skyrocketed 41% to $1.04 billion. The growth is broad-based: Hong Kong sales jumped 75% (aided by a 25% increase in agent count and new digital underwriting tools), and Indonesia grew 40% on the back of the CIMB Niaga partnership. Crucially, New Business CSM grew 23% to $320M, proving this is highly profitable volume, not just top-line fluff.
U.S. Stop-Loss Repricing Takes Hold
After struggling with severe medical inflation (8.5% trend) throughout 2025, the U.S. medical stop-loss business is Stable and Reversing prior margin compression. The company achieved a 17% average price increase on renewal business. Better yet, because smaller competitors are retreating from the hard market, Sun Life grew sales by 43% without sacrificing underwriting standards. Morbidity experience improved by $8M in the quarter, validating the 1/1/25 pricing cohort.
SLC Management's Bumpy 'Transition'
Management has touted SLC (now fully consolidated after $2.4B in buyouts of BGO and Crescent) as a 20% CAGR growth engine. Yet, Q1 fee-related earnings Decelerated sharply, dropping 25% YoY. Management blamed seasonality, bonus accruals, and the absence of prior-year catch-up fees. While they promise a 'solid rebound' in H2, SLC generated just US$32M in underlying net income this quarter. The newly integrated $400B global platform must quickly demonstrate revenue synergies to justify the capital deployed.
MFS Continues to Bleed Assets
The structural shift away from active U.S. equities continues to punish MFS. Net outflows were a staggering US$16.3B in Q1 (compared to US$8.1B in Q1'25). While MFS managed to keep underlying net income roughly flat YoY through higher average net assets (buoyed by market appreciation) and a 36.0% margin, the core issue of retail investor flight remains an unabated, Stable headwind.
Capital Buffer Depletion
The SLF LICAT ratio experienced a sudden Reversing trend, plummeting from 157% to 143%. While heavily telegraphed—10% of the drop was the cash deployment for the SLC affiliate buyouts—the remaining 4% drop was driven by market impacts (flattening yield curve, poor real estate returns) and the $145M MetLife legal settlement. At 143%, capital remains perfectly adequate, but the days of boasting a 'massive excess capital' war chest to fund surprise mega-buybacks are temporarily paused.
AI & Digitalization Yielding Real Cost Saves
Digital investments are moving from buzzwords to bottom-line drivers. In Canada, AI-enabled underwriting increased straight-through processing to 40% for eligible individual life policies (up 50% YoY), slashing average issuance time from 25 days to 11 days. In Malaysia, an AI-assisted Talkbot is handling frontline servicing. These efficiency gains are vital for defending margins in mature markets.
Other KPIs
Accelerating. AUMA grew 12% YoY. Canada remains the reliable anchor of the enterprise, delivering $370M in underlying net income (+7% YoY). Fee income is rising on higher asset balances, offsetting slightly less favorable insurance experience in the quarter.
Decelerating. Revenue fell as Sun Life executed its strategy to aggressively reprice or exit underperforming Medicaid dental contracts. While this shrinks the membership base and top-line, it is intentionally designed to improve the loss ratio. The business remains in a multi-year turnaround.
Guidance
Decelerating in the near term, but management explicitly expects earnings to 'rebound solidly over the remainder of 2026'. The integration of BGO, Crescent, and the incoming Bell Partners acquisition is expected to create a unified $400B platform capable of cross-selling to large institutions.
Stable/Slow recovery. Management confirmed the external environment remains pressured. The focus remains on cutting expenses to match the newly lowered premium base following Medicaid exits. No promises were made regarding hitting the previously touted $100M profit target.
Stable. The board authorized a renewed NCIB to buy back roughly 1.7% of outstanding shares. Management noted that share repurchases will be gated by cash generation at the holding company (currently $1.3B), prioritizing organic growth and dividend funding (which was just increased by 4%).
Key Questions
SLC's Path to 20% CAGR
With Q1 fee-related earnings down 25% and underlying net income falling to US$32M, the 'transition year' narrative is doing a lot of heavy lifting. What specific, hard catalysts in H2 2026 give you confidence that SLC will return to its 20% CAGR target?
MFS Outflow Floor
MFS retail outflows accelerated to US$16.3B this quarter. Is there a structural floor to this bleed, or should investors expect this pace to continue as long as active U.S. equity strategies remain out of favor?
U.S. Dental Shrink-to-Grow Timeline
You are intentionally shedding Medicaid dental revenue to improve the loss ratio. At what point in late 2026 or 2027 do you expect the commercial dental growth to outpace the Medicaid run-off, returning the overall U.S. Dental segment to top-line growth?